Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Immatics N-V stock | $14.64

Learn how to easily invest in Immatics N-V stock.

Immatics N.V is a biotechnology business based in the US. Immatics N-V shares (IMTX) are listed on the NASDAQ and all prices are listed in US Dollars. Immatics N-V employs 320 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Immatics N-V

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – IMTX – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Immatics N-V stock price (NASDAQ: IMTX)

Use our graph to track the performance of IMTX stocks over time.

Immatics N-V shares at a glance

Information last updated 2021-09-12.
Latest market close$14.64
52-week range$8.75 - $16.30
50-day moving average $12.57
200-day moving average $11.97
Wall St. target price$24.30
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-4.61

Buy Immatics N-V shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Stocks, Options, ETFs, Cryptocurrency
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
Sofi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Stocks, ETFs
$0 per month
Download and sign up with; approved accounts receive a free stock slice worth up to $70, selected from 9 popular stocks.
Open an account
Commission-free trading in stocks and ETFs with a social networking twist.
Stocks, Options, ETFs
Get two free stocks valued between $3.00 and $300 with a deposit to any new account.
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Immatics N-V stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Immatics N-V price performance over time

Historical closes compared with the close of $14.64 from 2021-09-17

1 week (2021-09-10) -1.08%
1 month (2021-08-19) 25.24%
3 months (2021-06-18) 24.07%
6 months (2021-03-19) 3.17%
1 year (2020-09-18) 59.30%
2 years (2019-09-15) N/A
3 years (2018-09-15) N/A
5 years (2016-09-15) N/A

Immatics N-V financials

Revenue TTM $29.9 million
Gross profit TTM $-35,832,000
Return on assets TTM -33.16%
Return on equity TTM -5802.34%
Profit margin 0%
Book value $1.22
Market capitalisation $931.1 million

TTM: trailing 12 months

Shorting Immatics N-V shares

There are currently 2.1 million Immatics N-V shares held short by investors – that's known as Immatics N-V's "short interest". This figure is 1.3% up from 2.0 million last month.

There are a few different ways that this level of interest in shorting Immatics N-V shares can be evaluated.

Immatics N-V's "short interest ratio" (SIR)

Immatics N-V's "short interest ratio" (SIR) is the quantity of Immatics N-V shares currently shorted divided by the average quantity of Immatics N-V shares traded daily (recently around 105779.75522693). Immatics N-V's SIR currently stands at 19.61. In other words for every 100,000 Immatics N-V shares traded daily on the market, roughly 19610 shares are currently held short.

However Immatics N-V's short interest can also be evaluated against the total number of Immatics N-V shares, or, against the total number of tradable Immatics N-V shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Immatics N-V's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Immatics N-V shares in existence, roughly 30 shares are currently held short) or 0.0723% of the tradable shares (for every 100,000 tradable Immatics N-V shares, roughly 72 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Immatics N-V.

Find out more about how you can short Immatics N-V stock.

Immatics N-V share dividends

We're not expecting Immatics N-V to pay a dividend over the next 12 months.

Immatics N-V overview

Immatics N. V. , a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct therapeutic modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its ACTengine product candidates are in Phase I clinical trials, which include IMA201 that targets melanoma-associated antigen 4 or 8 in patients with solid tumors; IMA202 that targets melanoma-associated antigen 1 in patients with various solid tumors, including squamous non-small cell lung carcinoma and hepatocellular carcinoma; and IMA203 that targets preferentially expressed antigen in melanoma in adult patients with relapsed and/or refractory solid tumors, as well as IMA204, an anti-tumor therapy, which is in preclinical studies that targets tumor stroma cell. The company's TCR Bispecifics product candidates, which are in preclinical studies includes IMA401, a cancer testis antigen for the treatment of solid tumor; and IMA402 for the treatment of solid tumors. It also develops IMA101, a multi-target precision immunotherapy; and IMA301, an allogenic cellular therapy product candidate.

Frequently asked questions

What percentage of Immatics N-V is owned by insiders or institutions?
Currently 32.882% of Immatics N-V shares are held by insiders and 33.572% by institutions.
How many people work for Immatics N-V?
Latest data suggests 320 work at Immatics N-V.
When does the fiscal year end for Immatics N-V?
Immatics N-V's fiscal year ends in December.
Where is Immatics N-V based?
Immatics N-V's address is: Paul-Ehrlich-Strasse 15, Tübingen, Germany, 72076
What is Immatics N-V's ISIN number?
Immatics N-V's international securities identification number is: NL0015285941

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site